Abstract
Levodopa-induced dyskinesia (LID) is a common consequence of effectively treating PD. Management depends on recognizing the pattern and timing, in response to levodopa doses. Thus LID can occur at the peak effect of levodopa (mainly chorea) or when the levels are lower or in-between doses (usually dystonia). In addition, evaluating the level of disability associated with the movements is important, as not all LID requires treatment. For peak-dose LID, reducing dopaminergic drugs is helpful. Specific treatment includes amantadine. Off period, or low-dose LID, often responds to increased dopamine levels by treating the OFF periods. Prevention of LID is key by keeping individual doses of levodopa as low as possible but with good motor control in the long term.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30(1):80–9.
Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, et al. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9(11):1106–17.
Fahn S, Oakes D, Shoulson I, Kieburtz K, et al., Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.
Ferini-Strambi L, Marelli S, Moccia M, Erro R, Ciacci C, Barone P. “Silly walks” in Parkinson’s disease: unusual presentation of dopaminergic-induced dyskinesias. Mov Disord. 2011;26:1782–178.
Fox SH, Katzenschlager R, Lim SY, Ravina B, et al. Movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S2–S41.
Freitas ME, Fox SH. Nondopaminergic treatments for Parkinson’s disease: current and future prospects. Neurodegener Dis Manag. 2016;6(3):249–68.
Hung SW, Adeli GM, Arenovich T, Fox SH, Lang AE. Patient perception of dyskinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81(10):1112–5.
Huot P, Johnston J, Koprich J, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev. 2013;65(1):171–222.
Manson A, Stirpe P, Schrag A. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis. 2012;2:189–98.
Nicoletti A, Mostile G, Nicoletti G, Arabia G, et al. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease. J Neurol. 2016;263(5):888–94.
Olanow W, Kieburtz K, Rascol O, Poewe W, et al., Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease (STRIDE-PD) Investigators. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–7.
Olanow CW, Kieburtz K, Odin P, Espay AJ, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.
Roussakis AA, Politis M, Towey D, Piccini P. Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias. Neurology. 2016;86(12):1152–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Fox, S.H. (2019). Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease. In: Reich, S., Factor, S. (eds) Therapy of Movement Disorders. Current Clinical Neurology. Humana, Cham. https://doi.org/10.1007/978-3-319-97897-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-97897-0_4
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-319-97896-3
Online ISBN: 978-3-319-97897-0
eBook Packages: MedicineMedicine (R0)